Novo’s Next-Gen Obesity Drug Beats Wegovy On Blood Sugar Control in Phase III

While CagriSema bested Novo Nordisk’s Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma’s 25% weight loss goal.